A mathematical model for targeting chemicals to tissues by exploiting complex degradation

Biology Direct

Bruce S Gardiner¹  Lihai Zhang³  David W Smith¹  Peter Pivonka¹  Alan J Grodzinsky² 

[1] School of Computer Science and Software Engineering, The University of Western Australia, WA, 6009, Australia

[2] Center for Biomedical Engineering, Department of Electrical Engineering and Computer Science, and Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

[3] Department of Infrastructure Engineering, University of Melbourne, VIC 3010, Australia

关键词: proteases;    Insulin-like Growth factor (IGF);    Prodrug;    Mathematical model;    Tissue;    Solute transport;   

Others  :  797097
DOI  :  10.1186/1745-6150-6-46

 received in 2011-02-21, accepted in 2011-09-22,  发布年份 2011

【 摘 要 】

Background

In many biological and therapeutic contexts, it is highly desirable to target a chemical specifically to a particular tissue where it exerts its biological effect. In this paper, we present a simple, generic, mathematical model that elucidates a general method for targeting a chemical to particular tissues. The model consists of coupled reaction-diffusion equations to describe the evolution within the tissue of the concentrations of three chemical species a (concentration of free chemical), b (binding protein) and their complex, c (chemical bound to binding protein). We assume that all species are free to diffuse, and that a and b undergo a reversible reaction to form c. In addition, the complex, c, can be broken down by a process (e.g. an enzyme in the tissue) that results in the release of the chemical, a, which is then free to exert its biological action.

Results

For simplicity, we consider a one-dimensional geometry. In the special case where the rate of complex formation is small (compared to the diffusion timescale of the species within the tissue) the system can be solved analytically. This analytic solution allows us to show how the concentration of free chemical, a, in the tissue can be increased over the concentration of free chemical at the tissue boundary. We show that, under certain conditions, the maximum concentration of a can occur at the centre of the tissue, and give an upper bound on this maximum level. Numerical simulations are then used to determine how the behaviour of the system changes when the assumption of negligible complex formation rate is relaxed.

Conclusions

We have shown, using our mathematical model, how complex degradation can potentially be exploited to target a chemical to a particular tissue, and how the level of the active chemical depends on factors such as the diffusion coefficients and degradation/production rates of each species. The biological significance of these results in terms of potential applications in cartilage tissue engineering and chemotherapy is discussed. In particular, we believe these results may be of use in determining the most promising prodrug candidates.

【 授权许可】

   
2011 Gardiner et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Zhang L, Gardiner BS, Smith DW, Pivonka P, Grodzinsky AJ: On the role of diffusible binding partners in modulating the transport and concentration of proteins in tissues. J Theor Biol 2010, 263(1):20-29.
• [2]Cohick WS, Clemmons DR: The insulin-like growth factors. Annual Review of Physiology 1993, 55:131-153.
• [3]Froesch ER, Hussain MA, Schmid Ch, Zapf J: Insulin-like growth factor I: Physiology, metabolic effects and clinical uses. Diabetes/Metabolism Reviews 1996, 12(3):195-215.
• [4]Baxter RC: Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. American Journal of Physiology - Endocrinology and Metabolism
• [5]Bunn RC, Fowlkes JL: Insulin-like growth factor binding protein proteolysis. Trends in Endocrinology and Metabolism 2003, 14:176-181.
• [6]Bach RS, Norton LA, Headey SJ: IGF-binding proteins - the pieces are falling into place. Trends in Endocrinology and Metabolism 2005, 16:228-234.
• [7]Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995, 16:3-34.
• [8]Mohan S, Baylink DJ: IGF-binding proteins are multifunctional and act via igf-dependent and - independent mechanisms. Journal of Endocrinology 2002, 175:19-31.
• [9]Fowlkes JL, Serra DM, Nagase H, Thrailkill KM: Mmps are IGFBP-degrading proteinases: Implications for cell proliferation and tissue growth. Annals of the New York Academy of Sciences 1999, 878:696-699.
• [10]Minchinton AI, Tannock IF: Drug penetration into solid tumours. Nature Reviews Cancer 2006, 6:583-592.
• [11]Grief AD, Richardson G: Mathematical modeling of magnetically targeted drug delivery. Journal of Magnetism and Magnetic Materials 2005, 293:455-463.
• [12]McBain SC, Yiu HHP, Dobson J: Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 2008, 3(2):169-180.
• [13]Owen MR, Byrne HM, Lewis CE: Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites. J Theor Biol 2004, 226(4):377-391.
• [14]Brown JM, Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer 2004, 4:437-447.
• [15]Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR: Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 2003, 63:5970-5977.
• [16]Kyle AH, Minchinton AI: Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culutre model. Cancer Chemother Pharmacol 1999, 43:213-220.
• [17]Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke m, Kenny L: Tripazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (trog 02.02, headstart): A phase iii trial of the transtasman radiation oncology group. Journal of Clinical Oncology 2010, 28:2989-2995.
• [18]Barta E, Maroudas A: A theoretical study of the distribution of insulin-like growth factor in human articular cartilage. J Theor Biol 2006, 241:628-638.
• [19]Breward CJW, Byrne HM, Lewis CE: Modelling the interactions between tumour cells and a blood vessel in a microenvironment within a vascular tumour. Euro J Appl Math 2001, 12:529-556.
• [20]Fowkes ND, Mahony JJ: An introdution to mathematical modelling. JohnWiley & Sons; 1994.